Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

Feb 5, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $17.00. The company’s shares closed last Friday at $12.28.

CouponFollow Extension

$17.00
OFF

Barclays Sticks To Its Buy Rating For Teva Pharmaceutical (TEVA)

2 weeks from now

businessinsider.com

$25.00
OFF

Teva Pharmaceutical (TEVA) Gets A Buy From Barclays

2 weeks from now

3 days ago · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

$25.00
OFF

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024 · Barclays has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE:TEVA), increasing the price target to $25.00 from the previous $22.00 while …

investing.com

$21.00
OFF

Teva Pharmaceutical Industries (NYSE:TEVA) Rating ... - MarketBeat

2 weeks from now

Oct 17, 2024 · Barclays lifted their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Thursday, August …

marketbeat.com

$19.67
OFF

Teva Pharmaceutical Industries (TEVA) Stock Forecast & Price Target

2 weeks from now

1 day ago · According to the 9 analysts' twelve-month price targets for Teva Pharmaceutical Industries, the average price target is $19.67. The highest price target for TEVA is $26.00, …

marketbeat.com

$25.00
OFF

Barclays Reaffirms Their Buy Rating On Teva Pharmaceutical (TEVA)

2 weeks from now

Nov 6, 2024 · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

$17
OFF

Teva Pharmaceutical Indus (NYSE:TEVA) Stock, Analyst Ratings, …

2 weeks from now

5 days ago · Teva Pharmaceutical Industries Ltd has a consensus price target of $17.7 based on the ratings of 12 analysts. The high is $26 issued by UBS on September 3, 2024. The low is …

benzinga.com

$25.00
OFF

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024 · Barclays (LON: BARC) has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE: TEVA), increasing the price target to $25.00 from the previous $22.00 …

investing.com

$22.00
OFF

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold …

2 weeks from now

4 days ago · Barclays boosted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, October 23rd. …

marketbeat.com

$25.00
OFF

Teva Pharmaceutical (TEVA) Receives A Buy From Barclays

2 weeks from now

Oct 23, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $25.00. The company’s shares …

businessinsider.com

$22.00
OFF

WCM Investment Management LLC Takes Position In Teva …

2 weeks from now

1 day ago · Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, …

marketbeat.com

$14.00
OFF

Barclays Remains A Buy On Teva Pharmaceutical (TEVA)

2 weeks from now

Jun. 29, 2023, 04:15 AM. In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $14.00. …

businessinsider.com

0%
OFF

Sivik Global Healthcare LLC Sells 30,000 Shares Of Teva …

2 weeks from now

19 hours ago · Sivik Global Healthcare LLC trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 15.0% in the third quarter, according to the …

marketbeat.com

FAQs about Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA) Coupon?

Should you buy Teva Pharmaceutical (Teva)?

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $22.33 average price target, representing a 21.49% upside. In a report released on October 16, UBS also maintained a Buy rating on the stock with a $26.00 price target. ...

What is the price target for Teva?

The highest price target for TEVA is $26.00, while the lowest price target for TEVA is $11.00. The average price target represents a forecasted upside of 1.55% from the current price of $18.60. Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. ...

Is Teva Pharmaceutical Industries a good stock to buy?

According to analysts, Teva Pharmaceutical Industries's stock has a predicted upside of 23.89% based on their 12-month stock forecasts. Has Teva Pharmaceutical Industries been upgraded by Wall Street analysts recently? Over the previous 90 days, Teva Pharmaceutical Industries's stock had 1 upgrade by analysts. ...

Should you buy Prasad pharmaceutical (Teva)?

According to TipRanks, Prasad has an average return of 3.0% and a 46.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $22.33 average price target, representing a 21.49% upside. ...

What is the forecast for Teva Pharmaceutical Industries stock?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Teva Pharmaceutical Industries is $18.89, with a high forecast of $26.00 and a low forecast of $11.00. Should I buy or sell Teva Pharmaceutical Industries stock right now? ...

Do Wall Street analysts like Teva Pharmaceutical Industries?

Do Wall Street analysts like Teva Pharmaceutical Industries more than its competitors? Analysts like Teva Pharmaceutical Industries more than other "medical" companies. The consensus rating score for Teva Pharmaceutical Industries is 2.78 while the average consensus rating score for "medical" companies is 2.76. ...